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Figure 1 Discovery 0' cephalosporin C
t Acid hydrolysis
7-amino cephalosporinic acid I,J-ACA)
(1960)
Mould from C. acremonium
(1945)
IX \\lave of Cl'phalosponm enable (FIgure 4) 3 mlcro-
bioi glcaI c1assifi anon to be made. 111 wll.lch (t'phenu are
divided into cvel1 groups ( igure 5) a cordmg to the
antib tenal spc tnll11.
he development of numerou compounds. wruch were
tntroduced in chtlJ a.I pra 0 e. all \ cd ccphelTlS to be diVided
into three phann3coklllctic groups a rdmg to thclr ~ppan:nt
e1l1nin,oon half-hfe igure 6).
In 1964....phalouull nt! ephal nc:Lne were mtrodu ed 111
Iinic~1 procti .... foil wed b cefuzolm. c:phaloridll1e \\ ule
fir.>t cephelll \Vlth a a.zolium heter cycle sub limem.
~ulton,lInld '\. ryrothrvl'lll In,1 pl'llIl'Ilhn ; werc the forenlllnep.>
III .111 IIlll'nSIVC ~u cc~~litl rell'arch to dl\cova Ill:' . Ilnbacrertal
.1[.:cnIS, Many tcams wcrl' !ookll1g for Ilew ,ompoulld~.
c\peClall} rhosl' wah .l hroad .1I1t1hactenal spccrrum.
he \u('(C" of pellll'llhll • h,ld an uncxpcclnl l"I l'n: .111
lIH:rl·a~lIl[.: Illllnbcr of S/IlI'''r/'',-.'r1'll., 1111f1"1> ISO!Jtcs n:sl;[all[ l\)
l'l'rllcdlln • In London hosl It.ll~ spread pro 'rcs~lvc:l ,111
round thl' world. Rt'se,Hch IIltO Illwd Jllnba tenal agcnts
wa\ e'\(trelllely Illlfl<, nant. Mall compounds With annb:lc-
tCTtal Jctlvity Wl"re discovered ,lnd S reened agatllsr S, 11111'/'115
i~ol. te re\lst. II[ to l'el1lClllin G, rythromycin. vallCOIllYClIl,
1l1cthlllllll1 and oxaCIllin were dlscovt:red or ynrhc\lZt"d tn
rhe I 9511s.
In Sardl1l1a. In 1945. G Urm7U dIscovered that fenm:ntarion
produ ts extr.lcred tTom "'flh '!<'SI'oJr;lllll 11 rm1lIIl;1I11l I.olatcd
(rom Ihe sca near a lcwage ourf.,11 at .agh3ri.. ardlnl,
exhllltcJ allli-Gram-p ~Itl\'e acnVtrlc,. The femll:nration
extracts were succeS5fillly administered locally for Ih tl'e3t-
mcllt of wound infections [II. A Brotzu w. unablc 10 puntY
the C. I1rm,","illll extract . he contacted the xford team who
h. d bcen u e ful with pemcllIlI1 to exmlCt 3nd purify the
'otllponenrs of rhl l~nllcntan()n.
Newt n and AI> . h.1111 li~covcred ccphal sp rin . 111 11)55
121 cphalosponn. W;I~ ounu to have cvcral rcmark. hie
properne.. bCll1g acnve 31-':1il1. t r: rhrlirili". «>Ii, '"I"wllrllll /y/,},i
.md thc Oxford strain of '. Illlrr1l$. but aI 0 reSIStant to
hydrolySIS b peniclUmasc trom Btloll1l5 S111'/ilis. The chcml a.I
stm ture wa.s elucidated m 1'J59 131. In ILJ60. small amounrs o(
7 -allllllo-ceph.llo~porantc .lcld r -A . ) \ ere obt311lcd hy a td
hydrolysl of ceph.lo. ponn (FI~llrl: I).
A hemi .11 pro edurc h which Ihe a-amino. dipy! ide-
ch. in could be rcmoved 10 pro uce 7-ACA In good )'leld \ a.~
dcveloped in 19(,_ [41. Four da.~~lfi alions h3\'c been
described: bIOlOgical 151. microhlOlo!;i al 161. chcml 'aI P.lli
. nd pharmacoklllen [61.
heml a.I Ia ifican n I~ made ccorlLng to rtng altcratlom
or b· sub tltuenl 31teratlon (Flb'1.lre 2 and ).
orrcspondlll' author and repnl1l requests: A. I3ry\kler. -Iilll 31
Ph nmcology of Antl-lIlfeetlw\. Hocch'l Marl Il I~om\d. JOZ. rollte
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Figure 3 Cephems: classification 3. che·














Wav. .. Gram-negative badll (Case)
Figure 4 Successive waves of cllphems.
Wave 5 Gram-negative badll (ESBL)
Man compound \ ere synthesized and the e composed
group I of the microbiologi al clas i6caoon. These analogs
were prepared to overcome, . omc,,)' resist:!nce to penkillin G.
The second aim was to prepare compound~ With a new -3
side cham co avoid metabolism and to lengthen the apparent
elimination hnlf-Iife. nc compound. cef.1zolin. posses~e a
long apparent half-life.
The sllccessful introduction f ampicillin in clinical practice,
which exhibits anu- ram-negative activity. was rapidly
followed by the emergence of clinical isolates resist:mt to
ampicillin by the production of broad spectrum ~-bctamases.
Research for new cephc01 denvativl..-s designed to overcome
~-I, tam. e production in Gr. m-ncgative bacten. re wted in






















Lllllltpd c,pcctrlll11 Bro.HI ~pe(trllll1
Group I Group II Group III Group V Group VI Group VII
I I Group IV I I ICateohol Cefsulodln AntiMRSA
Cephalothin II" liB cephems cephems
Cephaloridine
Cefazolln
Cephradine Cefamandole Cefoxltln C-3'-quatemary
Cephaplrln Cefuroxlme Cefotetan ammonium
Cephacetrile Ceforanlde Cefmetazole cephems
Cefonicld Cefbuperazone
Cefminox
Figure 5 Cephems: microbiological olnssilicallon.
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Figure 6 Ceph "'s pharmocoklneliCS classlhcallon
Ar Ihe begllllllllg of thL' I<)7()~ rcp m appe3rt:d Ih. I cerl31l1
~pe(lel of SIrt·/)/I.m)'rf pr \duced 7-'X-II1l'thoxy ceph.1 punm
161. 1I.III1L·J cephamyclTl5. ThL: pre>('11 'e of J 7-(.(-lllerhoxy
~roup In rhe c<'Jlhelll nng W.1I !<llllld ro bL: .IS onML,d wllh high
rC>ltranCL' t<J hvdrolySi by mO'1 p-berama~c>. Dunng tilt'
IL.I7(1\ \e\'l~r. 1 Ilew (eph.110 ponns wtlh useful JellvlI)' Jg:1I11 r
t;r.U1HlegJ(l\'L" b.lnUI \VL'fe prq'JrL:d by Illnher .llrerauom of
Ihe C-.\ .Iml C-7 ILI.·- 11.11111,
Two IlllportJIl! dllcovL'rlL" III Ihe tiL'lJ of cephellls wer...
reported: Ihe .')'11 1ll ... lhoxy III II no reslJue .11 Ihe C-7 po,mon of
IhL: eplwlll nlll:: (as III cdiHOXlllle) . lid IhL: rhiollle:lhyl-
letr.uole nng (.1\ III cef31ll3I1Jole). wlll'h Ie, ds I cnhaneelllell!
of 111 \'llro .1 Ul'lty. Thc,,' compounds of group II Wl"fC
lI11ruduccd III chlllcalpra II L: m ILJ7,)-HO. 111 gt:l1cr.ll, rht: .ll('
ks~ JCllV", Ih.1II group I 'ompounu\ J~Ill>1 sr3ph 10cocCl Jml
'IreplococCI bur arc mort: ,1(tI\,(" ,11.,"111\1 dL'd"d ;r.UI1-
ne~llve ba 111i AU Ih e ,ephL'Ill' POS~t:t ,111 al'ral'L'1ll
L'1l1l11nation halt:'h e rang frolll I 10 .\ h. Ol1e eOlllpoullJ.
cdi\lllcld. \\'Ith a lIIo,hticatHlIl 011 Ihe .-.\ IL·rr.1701,,1 nllg.
h.wlIlg J ~ll1Joll\,1 f!TOup III 1t:3d of 3 lllL:thyl group, pm\c t:> 3
long 31'1" renl ehnlln3tlOn halt:'hfe of S h 161·
A onnnllou~ n w f nc\ compoun Is ISsued Irolll ehcllllcal
altl' ,nOll conduClt:d 10 tic ign new Jenv, tlves to overcolllc
~-bcralll:JSe hydr ly 15. allo\VL'tI dOraXllnL:. the fil"il com-
pound of ",'TOUp III. to be ievdoped ILJ,JOI·
In pa r.illcl , t\ 0 rvpes of compounds have heen ynthe izcd:
-a yl ccphalo, ponn repre cllled by eefopcrazonc. r_-
allllllo-S-tlu3Z Iyl eephalolponnc; rcpr~cmed by eefotaxl1n....
all ot" thL:m arc IIlcluJL:d 111 group III. A gwen ('phem call be
assJgncti to brrouP Ill. if It P <; CS\t:~ al le:J5t two of Ihe
(ollowlIlg ch,lta tL:r1S11CS: the chmllcal \lruCtllrt' Illdude a
2-allllllo-S-lhl:lzolyl ring; \t. blltry 10 hroad-speetnlln 'X-
I:t talll:JSt: hydrolym; gooJ aetlVlry :Ig;llll t Gr,lIl1-ncgaovc
bacilli. e.g. nlerobaclenaceae. or fl OdlOl15 .ram-negalJ\'L·
hacllh: .1Ilnp,,:udOllIOn.ll 3 IIVlry (Figure 7).
CefOl. xlmc W.5 the lim 2-amin -5-lh.lll 1·1 ephelll
havlIlg J y" IIlcthO;>;YlIllltlO remiue t -7. The -3 cham
IS .In 3Cl'tQXylllt:lhyl mOIt:ry. The s)'"-mcthoxyllluno woup r;
I'C pomlble for the hi~h st.lbiliry to hydroly I b, broad-
spectrulll P-Ia t31l13\es.
ThL: Illtrodu lion <) rhL: 2-allljno- - -thl. zolyl nng In th...
7 Ide cham 1\ a Ill.uor atlvance III ceph.llosp nn r...sear h. Tim
nng 1\ re\pofl\lbll' lor tht: brc.lkthmugh U1 ,lIlnb.1 ten31
3Clwil)'.;r; efOl.1xmIL· IS more than lOll ome more pOlem
thJIl Cd:,Ill. ndolL: :l~II1, r Gram-negatlve bactcna (FIgure H).
1I111CrOlIS nther 2-anuno-5-rhl3Z0Iyl eephelll' wert:
syndlc.lzcd and Introduccd 111 !.true I pr.Jeoce ThL:}' JdTcr
frolll c!oraxJIlu: III their subsoruenrs r p Itl n 3 of the
L:pht:1ll nng. Al Ica,r livc Illp unds III addioon ro
celillJ, 1111(' WL:rt: illtroduct:d m lal1l al pr:leo e: efuzo:'alllc.
ccfrnax lIle. ccfodlZIIIIC. efrazldme, cti,len Xll1le Lgure 9).
ThL: :-3 substituent IS responsIble: tor phamlacokmetlc
propemes. hl~hbghlcd III Cl' rnaxonc. whJch poss es a
lrtaZllle subsotllted nng. or cdodwme, \ Iuch has 3',5'-
dlsubsutuled du:l.Z Iyl nng 11 11 (Figure 10). he btter
sub oruelll IS also rlOSp nSlble (;'r 'non, nnbaeten I OVlry',
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\uch the Immune-stullubring pr pern \ 0 cfodizime 1121.
The -3 m lety also oncnbut~ t . ntlba tcnal tlvity. Tim
fa t I highlighted by the in cuJum size elfc t [131 or by
differenti 1 • crivicy gainst IITplorom p"e"mo/lial' is lares
r canr t pemcillin (fab! I nd 2). Agaimt such
llIuLudrug rc I5tant S. I"W/I/lOII/Of tr:Iin. Illy cc oraXlme and
c:frnaxone exhibir good and rher3peuric activity. e tizox-
lin '. c t2Z1dune and cefodiZlme arc: devoId of anribact na1
CtlVlty 3gaJtlSt the e isolatcs [14J ( igure II).
Figure 8 Cephems group III.
A thud line 0 mpound\ was obra\l1cd b II1rr ducrion of
. n oxygen 3tOlll \11 rhe cephclll nng IllSt . d ( ulfur at III
rJ51 ( Igure 12). The: first deriv. rive introduced in clinical
practice W3.\ 1. t:l1ll xer [t 51. Lat:lrn xef i . tive agaillSt
nterobactcriaccae harboring broad specmll11 !l-laCtaJ113.\e
and evcn cxtcnded spectrum !l-lact:unases (E BLs). Howevl"l'.
latallloxe has low CClVlty or I iJ1actlvc against ram-positive
CI. L talll xe was given up due to l xpc red adverse
even . The pl'C\en e of an N-methylretr3zolthio ring ar -3'
t 2000 Copyright by the Europelln Society of Clinical Mlcrob ologV and Infeotious Diseases. eMI.6 (Suppl. 3). 13-21














Figure 9 C phem group III
Table 1 Inoculum So1e cHeer III Vitro (MIC mg/l) (13]
E, coli K, pn8umonloe
CFU/ml 5 • 106 5 , 10' 6 ' 10~ 5 • 10'
Cel ISxlme 006 05 006 05
Ceft"sxontl 006 1 0 025 4,0
ColIsmjlnll! 012 80 012 80
h,l\ heell ~h()\\'n 1,1 he re'llOlIslbk lilr hyp()prothrolllblllJelllJ.l
(illhihirioll lIr VIt~1I1111 K-q 0.'11 Ie reJner~\e) alld ~1Ir.,hu,e-hke
l.'Il~(1 (1IIIlIhlll()1I or aklchyde ddl)rdrogenawl, The carhoxyl
group ,It '-7 ,',III ,',n C "btdcI dy rUlI'nOIl 1161
HOWCVCI, thl' C-J' - .hydroxylllelhylll'tr.lzolylthl< IIIl'rh,,1
b'Tllllp olllollloX<"I' dOL", 1101 lIllllhlt thl' aldchyde ,k'hydrngeIlJ~l'
T 112 B" 3 510 45 hours
Figure 10 Gooup III B cephems wilh long apparent ehmlnallOn half hfe
1171 Jnd I~ les~ mhlilltmg coward \"ItJIlUIl K-epoxJde rCLIlln.,~~
tlUII the -Illeth ,I dcn"JtI\'c, Flollloxcf I~ It", Jetl\'" Ih.m
bL1lllox"t' a~":Illl\l Elllcrob. tenaceae prndu mg cia" I p.
1.lClJIllJ<"~ hm \110\\'\ ,I f: 10.1 III VIUO Jll 1\'1 ['\' ab':lln\t ,QIll-
!'("jtl\'c cotcl. lher ox..,-I-el'phellll ha\e hCl'n Ylllht:\lzed
hill 110m' of ItWIll re'lehed Ihe de\'c!lIpllll'lIl lage [(,I
TOtby, Ihrcl' tepl1.llo ponn of group III rellUIIl lll:lJor
,lIltlb~nen,ll dnrg~ IIII' ITe rmenr of ~c:V('fe IIlfi.,ct1()n~: rdOl~x­
Illll', cdinaxone ,lIld ct'linldlllle, A rl'\'I\'a! or cd'lJZtlXlllle "
expcncd III Japal1 ,1\ ,III tlr;ll IlUIlOKIJ prodrul;:, bUI due 10 til<'
b ," I' JClJVll)' Ji-':IIIL~I S. 1"/1'/1"/1'"1111' "oble' n' 1~lalll 10
pt'l1lCllll1l G, tim 'ompoulld \1'111 h,l\'e rc Inned chnicll
Illtheao n III rC\I"r.llOry cr.1l'1 Ill(CCtlOlh,
U~ctcn~ ,1Ie very (Ie;\:Iblc ano al\\ JVS foulld J wa [() esc pc
,lIlllbaceenal ,ellVIt\', 'roup III COlliI' ulld; hJve wc,lkl1c "',,
Ihey an' devoid or ,ll'II\'lt)' .lb'dJll\1 "olal'" produ':lIlg cl.w. . p.
1.1l'l,lI1U'e (',g. Citl"/"IfIl"In'/Il1dll, ,\1"'X'/I"'/I., 1II"~'"I1I" ","i"
1I1111f1'; (,'II.< , r:1l1cmlJ"tn ~pp,) ,1I1d ,Hc hydmlyzcd b~ ESUL, \Ilch
J' TEM-J ,111<1 oehl'r T ~llzYl1les, Jlld 'H -2 Jnd other
')HV enZVllIes, willeh h\'llrolyze CefillJXlllle nd ettazldIDle 111
v,m u' Jl'~'fCe', 'SBL l'1l2\'llIl" ,Ire CIlC Illller'd IIIJIIlJv 111
KId, idl" IlIIrllll""""r bUI an.. a~() t' UII,I III neher r:lltrn,h.lttrr-
Tnblo 2 A lIvlI,e, 01 cephcms agDIOSI S pneumonme wllh d,fforonl pallo,"s of reSlstanco 10 penlcl'"n G [14]
Peni·S (MIC ... 0,12 mg/l) POOl·1 (MIC 0,12 1,0 mg/L) Penl-R (MIC 1,0 mg/L)
MICso MIC90 MIC60 MICltQ MICso MIC80
Cofolax,",o 003 003 0.25 '0 10 20
C ftnaxon 003 003 025 10 10 20
C ftazldlln 025 025 20 160 160 160
CC'lIzoxllno 006 006 05 80 160 160
Ce'odlllm 003 003 05 20 20 40
C 'pllomo 001 003 012 05 05 10
Celeplme 003 012 012 05 10 10
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Figure 11 Cephcms group III Oxa·1·ccphon1s,
Figure 12 Cephems zwiltorlonic compounds.
Rln~~~O N-N








joceoe species. The thIrd weak paine (ex ept for cef[Jzidime) is
the poor :ultipseudomonal acnvlty.
Research ,lid not srop afrer rhe introduction in clinical
practice of members of group Ill. The t.1rget was r enhance
antipseudomonal. antl~[Jphylococcal aCtivities and to over-
come das Il--lactalllast' .
cfsuloJin [I I'll and ceftaz.idime were the first cephalosporin
wlth llllprovcd activity PSl'IIdOIllOllOS f1Cmgillos'l to be used in
clinical setring. Tlwy bear a I-pyridinium group ar the -3
posICIon. These rwo compounds are dianiomc compounds
119J (Figure 13). In the mL':lnmlll', IC 1V:t~ decidl'd co ahand n
the usc of the N-ml'chyltettazolylthio moiety at C3 due co
un~ccept~hll' side-effects. Group IV, con[Jining -3' qua-
remary ammonium cephem 120,21], arose from tillS resear h
(Fib"Jre 1-1). These azo!ium dcnvatives ~re ZWltcenomc
compounds (Figun: 15). In group IV. orher hemical
a1reratiollS have bet:n done. In order co iu ·rease antipscudo-
mona1 activity. llltroduccion of the 5-amillo-2-thiadiazolyl
ring instead of cbe 2-amiLlo-5-thiazolyl ring (i,t:. cefclidin.
cetluprenam) enhancL'S the antipseudomonal activity bllt leads
t decreased activity against Enterobacteriaceae 122] (Figure
'16). efpirome. ceft:plnle, cer.lidin and cefluprcnam have
beell introduced in cliluc:tl praCtlcc.
Became of their zwicrerioni nature. these compounds
can <:mer through addirional porin channels and rapidly
r<:ach thdr PBPs targets by exhibiting poor affinity for
cia 13-lactalnase. which arc loc~ted in pcriplasmic space .
However. these compounds are hydrolyzed by ESBL and
none of them show an elimination half-life ahove 3 h in
healthy volunteers.
In order to mcrcase ano-Gram-p itive. crivities, different
chemica] III dific..1tions h. VI' been proposed. e.g. a -3 vinyl
l11oit:ty or an hydroxyimino hain instead of. methoxyinuno
cesidue ac C-7 of the cephem ring [6]. These c mpounds
showed a igni6c3m enhancement of antisraphyl.ococcal
actlvity. Intr ducti n of a Illonofluorolllcthoxyimino group












































Figure 13 Cephems: group IV (2) classificallon,
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Bryskier Extending the antibacterial spectrum 1\1
e-3' quaternary ammoolllT'l moiety
Figure 14 Group IV C·3' ammonrum
qual rnary ccphcms
-8 H,C-0





• Improve antlpseudomonal ctivly
• decrease anti enterobaderiaceae activly
Figure 16 Ceph ms group IV chemIcal allerallon
,It"lIVlry ,1~,1I1l\1 1Il0,l bactl'n~ ,IS . Illp.lred with the Illl,th-
)xy"nil1o cOUllIcrpart 161. Ho\\'.:'''er, th.:' ,lIllipscudoll1( nal
activity I' neVl'r ~,lll,l: clOr)', :" P. Ill'ru,~;IIM" quickly ()VerCOllll'~
th... annb,ll'terlJI ,lCu"lry of ne\\' COlllpoutld~.
Cephclll' thaI hclnng lO ~rClIII' I pmscss twO r Illore of
lhe !()lImnng chara 'Il'n,tll'\"
thc pre: ence of a ~-3' qualcm3l'y ,lIlUUOtllUlll silk c1um:
2 a broad annbacterial pecmnn including P, acnlgIlH'StI:
3 go d annbactcnal aetl\'lty ~g:llnsl Emerobactcnaccae
I,obt... produ lIIg da , ell.zyrn....
They also have to fulfil the ,ldinlt1on I W-0IlP III [61,
II the C-J' 'I"ale:rnary allllllonlunl ,ollll'0und InrroJuc...J
Inr d1l1lC,11 lI'e or unda (h:vcloprnelll po\\e s the sallle
,lIllib~ tenal, li"lry J) ccfolaxllne, but they Jilrer by addtng
alltll"eudol1lClnal ,lCtlvity [2:\1. Dill' [0 the: '-3' Idc-cham,
rhe:re arc ditfcren (") ,1m Ill:': these: COIllPOIIIl :Is, Ag,Il1,11 -,
1""'II"wIIH,r, itTe PCCtlVC of the reSISt.l11CC phenotypc [0
pelllCillm ,the Illost ,C[lVc cOlllpoulld IS cefpu me:. Agamsl
pelU 111m G fl"I,rant S. I'/It'll II"'l/;a,' efepune ami CCf010pr.m
exlnhtt cOlllp,r,lhle, tlVlty to cdc)l. "lmc Cetlupn:n, tTl wa'
weakly active and cef, Itdll1 IS maClI\'t' 121],
New cephe:ms were neeJed Jg;tlnsl . lHerobaCll'nact'ac
produnng E 131. and P. """',~;II(lSIl. ew set.~ of ccplul ',p'mn"
whICh ompm 'd group V (FIgure 17), ,He CJtl'chol ,I'
I ndOlle-colll3lnmg cephcn~ (Figure IH) The\<: c tcchol or
p ndlluc I11melil'S are a[[Jchel! to the Q)omc rC<1duc, and
produce a bIfunctional mechanISm of a oon, PBPs IIlhlbltlon
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lage. The furthesl developed compound W;LS cefteco) [24).
ome denv.oves, such as RUS\lR63, exhibited go d . nti-
p eudomonal acnvlty, were able 10 overcome E BL produc-
lIon nd dispbyed good ,1J10st: phyl OC al activity [25.261.
Rt.'R-arch mlO catechol-contalllmg cephelll was gIVen up
due to the Jtfficult chenllsrry. IlIgh c st f pr dunion and n ks
of adverse events. a shown wllh cefteco!'
Toda research in the cephem field is Illore focLLsed on
n.lrrow pectrulll amibaetenals. The firsl narrow specmlm
ceph losporin. cefsulodin (b'TOlIp VI). w introduced III
climcal practice IJ1 the earl 19R()s. A renewal of interest n
narrow antibactenal spectrulTl cephems arose m respect of
methicillin-resIst nt . al/rell! (MR A) [27]. Many compounds
have been lIIvescigated for ami-MI~A , tivities. within
known f,ullIhcs. such as glycopcptid· • or new chemical
Chp-111lcal rnodlflc.ltlon
enrioC'S for human use. such as ox.1Zolidm nes. eveminomycin
or ne\ screened mpoun .
By chelllical alter:ltions of the -7 and C-3 ubsnruents of
the cephem nucleus. novel entities have been synthesized
withlll carbacephcms [2 ] or cephaJosponns (Figure 18). The
anlC type of research was ongom~ m the carbapenem f:lII1JJy
[29,30]. ThL group VII I composed of narrow spectrum
ephem. ne camp und IS currently und'r devc10pmcm -
M 02-l79 (RWJ 54-128). The di.fficult task is t produce
cephcms, \ hich provide activIty, gains! MRSA and gainsl
GISA trams. R.WJ 5-1-1_8 [31 J eems to be active agaillst both
MR A and vancomycin-re istam . allrCIIS ( I A) strains.
One known wealmcss of tills compound is the poor water
olllbliity. Prodnlg derivatives have been prepar.:d with
improved solubility [32J.
CONCLUSION
SlOce the first biological das ificaoon published by 'CalI-
aghan [5J in 1975, many extensive revicws in the field of
cephalo. ponns have been publi.shed [6-8.271. lassifi. Dam
evolved following the syntl,e is of ne\ chcmical tr1J ture
with novcl •ntibaclcrial a civi0 t.'S.
Catechol moiety
fixes on the oxine chain
Figure 17 Cephems group V
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Figure 18 Cephems." roup VII: cephems
designed for antl·MRSA activity.
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